Amarantus BioScience Holdings, Inc. (AMBS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Amarantus BioScience Holdings, Inc. (AMBS) with AI Score 52/100 (Hold). Amarantus BioScience Holdings, Inc. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Amarantus BioScience Holdings, Inc. (AMBS) Healthcare & Pipeline Overview
Amarantus BioScience Holdings, Inc. is a biotechnology firm developing diagnostics and therapeutics primarily for neurological disorders, including Alzheimer's and Parkinson's disease. Operating within the competitive healthcare sector, the company focuses on innovative solutions like the LymPro test and Eltoprazine, targeting unmet needs in neurodegenerative diseases.
Investment Thesis
Amarantus BioScience Holdings, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on neurodegenerative diseases, an area with significant unmet medical needs, offers substantial market potential. Key value drivers include the successful clinical development and commercialization of LymPro for Alzheimer's disease and Eltoprazine for Parkinson's disease. The company's gross margin is 100.0%. Upcoming clinical trial results for Eltoprazine and progress in the development of ESS for severe burns could serve as positive catalysts. However, the company's negative profit margin of -4995.2% and OTC market listing highlight significant financial and operational risks. The beta of -12.34 suggests high volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B, indicating a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00, reflecting the company's current lack of profitability.
- Gross margin of 100.0%, suggesting strong potential profitability if products are successfully commercialized.
- Profit margin of -4995.2%, highlighting the company's significant losses and need for additional funding.
- Beta of -12.34, indicating high volatility and a negative correlation with the overall market.
Competitors & Peers
Strengths
- Proprietary diagnostic platforms (LymPro, MSPrecise).
- Therapeutic pipeline targeting unmet needs in neurology (Eltoprazine).
- Cooperative research agreements with reputable institutions.
- Focus on innovative solutions for neurodegenerative diseases.
Weaknesses
- Limited financial resources and negative profit margins.
- Dependence on successful clinical trial outcomes.
- OTC market listing indicating higher risk.
- Small market capitalization and limited trading volume.
Catalysts
- Upcoming: Clinical trial results for Eltoprazine in Parkinson's disease Levadopa-Induced Dyskinesia.
- Upcoming: Progress in the development of Engineered Skin Substitute (ESS) for severe burns.
- Ongoing: Potential for strategic partnerships and licensing agreements.
- Ongoing: Advancements in the development of LymPro for Alzheimer's disease.
- Ongoing: Research and development progress on NuroPro, BC-SeraPro, and PhenoGuard platforms.
Risks
- Potential: Unsuccessful clinical trial outcomes for key product candidates.
- Potential: Regulatory hurdles and delays in obtaining approvals for diagnostic and therapeutic products.
- Ongoing: Limited financial resources and dependence on additional funding.
- Ongoing: Competition from larger pharmaceutical and biotechnology companies.
- Ongoing: OTC market listing indicating higher risk and lower liquidity.
Growth Opportunities
- Advancement of LymPro for Alzheimer's Disease: The Alzheimer's disease diagnostics market is projected to reach billions of dollars by 2028. Successful clinical validation and commercialization of LymPro could provide Amarantus with a significant revenue stream. The timeline for commercialization depends on clinical trial results and regulatory approvals, potentially within the next 3-5 years.
- Development of Eltoprazine for Parkinson's Disease: The market for Parkinson's disease treatments is substantial and growing. Positive clinical trial results for Eltoprazine could lead to regulatory approval and market entry, offering a significant growth opportunity for Amarantus. This could materialize within the next 4-6 years, contingent on trial outcomes and regulatory processes.
- Expansion of Engineered Skin Substitute (ESS) for Severe Burns: The market for advanced wound care products, including skin substitutes, is expanding. Successful clinical trials and commercialization of ESS could provide Amarantus with a valuable product in this market. Mid-stage clinical development suggests potential market entry within the next 3-5 years.
- Leveraging NuroPro, BC-SeraPro, and PhenoGuard Platforms: These diagnostic platforms offer potential for developing new diagnostic tests for neurodegenerative diseases and cancer. Successful development and commercialization could generate additional revenue streams for Amarantus. The timeline for these platforms is dependent on research and development progress, potentially yielding results within the next 2-4 years.
- Strategic Partnerships and Collaborations: Amarantus's cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University provides access to valuable resources and expertise. Forming additional strategic partnerships could accelerate the development and commercialization of its products. These partnerships could materialize at any time, providing ongoing growth opportunities.
Opportunities
- Expanding market for Alzheimer's and Parkinson's disease diagnostics and therapeutics.
- Potential for strategic partnerships and licensing agreements.
- Advancements in regenerative medicine and cell therapy.
- Government funding and research grants for neurodegenerative disease research.
Threats
- Regulatory hurdles and lengthy approval processes.
- Competition from larger pharmaceutical and biotechnology companies.
- Patent expiration and generic competition.
- Unsuccessful clinical trial outcomes.
Competitive Advantages
- Proprietary diagnostic and therapeutic technologies.
- Intellectual property protection through patents and trade secrets.
- Cooperative research and development agreements with leading research institutions.
- Focus on niche markets with unmet medical needs.
About AMBS
Founded in 2008 and headquartered in New York City, Amarantus BioScience Holdings, Inc. is a biopharmaceutical company dedicated to the development of diagnostic and therapeutic solutions for a range of medical conditions. The company's initial focus was on regenerative medicine before expanding into neurology, psychiatry, and ophthalmology. Its diagnostic pipeline features the LymPro test, a blood test designed for the early detection of Alzheimer's disease, and MSPrecise, a DNA sequencing assay aimed at identifying patients with multiple sclerosis. On the therapeutic front, Amarantus is developing Eltoprazine, a small molecule drug intended for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders. Additionally, the company is exploring the potential of mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating various conditions, including retinitis pigmentosa and retinal artery occlusion, in animal models. Amarantus also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company is also developing Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. Formerly known as Amarantus Bioscience, Inc., the company rebranded to Amarantus BioScience Holdings, Inc. in April 2013.
What They Do
- Develop diagnostic blood tests for Alzheimer's disease (LymPro).
- Develop DNA sequencing assays for identifying patients with multiple sclerosis (MSPrecise).
- Develop small molecule drugs for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia (Eltoprazine).
- Develop neurotrophic factors for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion.
- Develop neurodegenerative disease diagnostic platforms with application in Parkinson's disease (NuroPro).
- Develop oncology diagnostic platforms with application in breast cancer (BC-SeraPro).
- Develop platforms for neurrotrophic factor discovery (PhenoGuard).
- Develop Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product for the treatment of life-threatening severe burns.
Business Model
- Develop and commercialize diagnostic tests for neurodegenerative diseases.
- Develop and commercialize therapeutic drugs for neurological and psychiatric disorders.
- Out-license or partner with other companies for the development and commercialization of its products.
- Generate revenue through product sales, licensing agreements, and research grants.
Industry Context
Amarantus BioScience Holdings, Inc. operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and significant market potential. The industry is driven by innovation in diagnostics and therapeutics, particularly in areas like neurodegenerative diseases, where there are substantial unmet needs. Amarantus competes with both large pharmaceutical companies and smaller biotech firms, including ACBM, AFFY, BSSP, DECN, and ENDV, focusing on niche markets and innovative technologies to differentiate itself.
Key Customers
- Patients with Alzheimer's disease, multiple sclerosis, Parkinson's disease, and other neurological disorders.
- Hospitals and clinics that diagnose and treat these conditions.
- Pharmaceutical companies that may license or partner with Amarantus for the development and commercialization of its products.
- Research institutions and government agencies that fund research on neurodegenerative diseases.
Financials
Chart & Info
Amarantus BioScience Holdings, Inc. (AMBS) stock price: Price data unavailable
Latest News
-
Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
defenseworld.net · Mar 15, 2026
-
Contrasting Amarantus Bioscience (OTCMKTS:AMBS) & Progyny (NASDAQ:PGNY)
defenseworld.net · Feb 9, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AMBS.
Price Targets
Wall Street price target analysis for AMBS.
MoonshotScore
What does this score mean?
The MoonshotScore rates AMBS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Wesley Commissiong
CEO
John Wesley Commissiong serves as the Chief Executive Officer of Amarantus BioScience Holdings, Inc. His background includes experience in the biotechnology and pharmaceutical industries. Further details regarding his career history, education, and previous roles are not available from the provided source data.
Track Record: Specific achievements and strategic decisions under John Wesley Commissiong's leadership are not detailed in the provided source data. Therefore, a comprehensive assessment of his track record is not possible.
AMBS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Amarantus BioScience Holdings, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and less stringent listing standards, resulting in higher risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or mismanagement.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility and potential for manipulation.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags or material events.
- Consult with a qualified financial advisor before investing.
- Cooperative research agreements with reputable institutions (U.S. Army Institute of Surgical Research and Rutgers University).
- Development of diagnostic and therapeutic products targeting significant unmet medical needs.
- History of operations since 2008.
- Focus on innovative technologies and scientific research.
What Investors Ask About Amarantus BioScience Holdings, Inc. (AMBS)
What does Amarantus BioScience Holdings, Inc. do?
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing diagnostic tests and therapeutic products for neurodegenerative diseases, psychiatric disorders, ophthalmology, and regenerative medicine. Their key products in development include LymPro, a diagnostic blood test for Alzheimer's disease, and Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia. The company also develops Engineered Skin Substitute (ESS) for severe burns. Amarantus aims to address unmet medical needs in these areas through innovative diagnostic and therapeutic solutions.
What do analysts say about AMBS stock?
AI analysis is pending for AMBS stock. Without analyst ratings or price targets, it is difficult to assess the market's current expectations for the company. Investors should conduct their own due diligence and consider the company's financial condition, product pipeline, and the risks associated with investing in early-stage biotechnology companies before making any investment decisions. The company's OTC listing and limited financial resources should also be carefully considered.
What are the main risks for AMBS?
Amarantus BioScience Holdings, Inc. faces several key risks, including the inherent uncertainties of clinical trial outcomes and regulatory approvals for its diagnostic and therapeutic products. The company's limited financial resources and negative profit margins raise concerns about its ability to fund ongoing research and development. Competition from larger pharmaceutical and biotechnology companies also poses a significant threat. Additionally, the company's OTC market listing indicates higher risk and lower liquidity compared to companies listed on major exchanges.
How does Amarantus BioScience Holdings, Inc. navigate regulatory approval processes?
Amarantus BioScience Holdings, Inc. must navigate complex regulatory pathways to gain approval for its diagnostic and therapeutic products. This involves conducting rigorous clinical trials to demonstrate safety and efficacy, submitting detailed applications to regulatory agencies like the FDA, and complying with ongoing monitoring and reporting requirements. The success of Amarantus hinges on its ability to effectively manage these regulatory processes and address any concerns raised by regulatory agencies. Delays or failures in obtaining regulatory approvals could significantly impact the company's prospects.
How does Amarantus BioScience Holdings, Inc. manage patent expiration risks?
Amarantus BioScience Holdings, Inc. relies on patents and other intellectual property protections to maintain a competitive advantage for its diagnostic and therapeutic products. As patents expire, the company may face increased competition from generic or biosimilar products, which could erode its market share and profitability. To mitigate this risk, Amarantus must actively manage its patent portfolio, seek new patent protection for innovative technologies, and develop strategies to extend the lifecycle of its existing products. The company's long-term success depends on its ability to effectively protect and leverage its intellectual property assets.
What are the key factors to evaluate for AMBS?
Amarantus BioScience Holdings, Inc. (AMBS) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary diagnostic platforms (LymPro, MSPrecise).. Primary risk to monitor: Potential: Unsuccessful clinical trial outcomes for key product candidates.. This is not financial advice.
How frequently does AMBS data refresh on this page?
AMBS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AMBS's recent stock price performance?
Recent price movement in Amarantus BioScience Holdings, Inc. (AMBS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary diagnostic platforms (LymPro, MSPrecise).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available.
- OTC market listing indicates higher risk.
- AI analysis pending.